Astrazeneca (AZN) Other Non-Current Assets (2011 - 2021)

Astrazeneca has reported Other Non-Current Assets for 6 years, with the latest figure at -$447.0 million in Q1 2021.

• On a quarterly basis, Other Non-Current Assets changed N/A year-over-year to -$447.0 million in Q1 2021; TTM through Mar 2021 was -$447.0 million, a N/A change from a year earlier, with the FY2020 full-year figure at $506.2 million, up 18.0% from the prior year.
• Other Non-Current Assets was -$447.0 million for Q1 2021 at Astrazeneca, down from $506.2 million in the prior quarter.
• The five-year high for Other Non-Current Assets was $506.2 million in Q4 2020, with the low at -$447.0 million in Q1 2021.
• Average Other Non-Current Assets over 5 years is $190.4 million, with a median of $294.9 million recorded in 2018.
• The sharpest annual moves came in 2018 and 2020: Other Non-Current Assets jumped 74.5% in 2018, then increased 18.0% in 2020.
• Over 5 years, Other Non-Current Assets stood at $169.0 million in 2017, then surged by 74.5% to $294.9 million in 2018, then surged by 45.47% to $429.0 million in 2019, then gained by 18.0% to $506.2 million in 2020, then sank by 188.31% to -$447.0 million in 2021.
• The last three Other Non-Current Assets figures came in at -$447.0 million (Q1 2021), $506.2 million (Q4 2020), and $429.0 million (Q4 2019), per Business Quant data.